Atorvastatin decreased all LDL-subfractions to a similar extent (quantitative effect) whereas fenofibrate reduced predominantly dLDL and changed the LDL profile towards medium dense LDL-particles (qualitative effect). Since medium dense LDL have a higher affinity to the LDL-receptor fenofibrate may have a higher antiatherogenic potential than assessed by the reduction of total LDL-cholesterol and triglycerides alone.
This postmarketing surveillance study documents the therapeutic benefit and good tolerability and compliance of acarbose as mono- and combination therapy, even in elderly and multimorbid patients.
A total of 46 early postmenopausal women with elevated levels of total cholesterol, triglycerides, low-density lipid (LDL) cholesterol and lowered high density lipoprotein cholesterol (HDL) cholesterol was treated with spleen dialysate (Solcosplen), 2 x 2 tablets daily for 6 months. Serum estradiol levels rose from 42.3 +/- 15.4 pg/ml to 60.6 +/- 23.6 pg/ml and the Kupperman Index decreased significantly after 6 months of treatment. Also, a significant decrease of total cholesterol, triglycerides, LDL cholesterol, and an increase of HDL cholesterol was observed. The changes showed no correlation with the estradiol concentration and no side-effects were evident. Solcosplen is recommended as a beneficial therapy for women in the early postmenopause.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.